2010 May. Pharmahungary has got regulatory approval for a Tamiflu pharmacokinetic clinical study (ClinicalTrials.gov Identifier: NCT01130636). The study is sponsored by Pharmahungary and supported by F. Hoffman-La Roche. The expected starting date for patient recruitment is July 2010.

2010 March 4, Press release: Pharmahungary and Cellmid (Sydney, Australia) sign collaboration and R&D agreements to develop midkine therapies for myocardial infarction.

2009 Q4, 2010 Q1, Pharmahungary launches new services and products
- noninvasive ultrasound imaging of the heart in acute and chronic heart failure models

- uremia experimental models (partial nephrectomy)
- why spend time for in vivo or ex vivo experiments, buy rodent myocardial tissue obtained from custom design experimental protocols (e.g. ishemia/reperfusion, postconditioning, hyperlipidemia, etc.)
- myocardial infarction in large animal models

2008, Nov: Breaking news by Thomson Reuters:
A recent publication of Pharmahungary (Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458, 2007) has been selected by Essential Science Indicators as a Fast Breaking Paper in the field of Pharmacology & Toxicology